Vermilion Research - AcelRx Pharmaceuticals (ACRX) Vermilion Booster Shots: Attractive bottom-fishing stocks

Report

Vermilion Research

Dave Nicoski

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

For a trial to Vermilion Research visit our website at www.vermilioncap.com or contact our sales team at (952) 922-7500.

26/07/2017 13 EN

Underlying

AcelRx Pharmaceuticals

AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The company's DSUVIA? and Zalviso, are both focused on the treatment of acute pain, and each utilize sufentanil, for use in medically supervised settings. DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Zalviso is for the management of moderate-to-severe acute pain in hospitalized adult patients.

See profile

US00444T1007 NASDAQ Stock Market United States

Provider

Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

See profile

Analysts

Dave Nicoski

Other Reports on these Companies

GlobeNewsWire

AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program

AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program Key Opinion Leaders participating will be Stuart Goldstein, MD, Cincinnati Children’s Hospital and Lakhmir Chawla, MD, former Chief of the Division of Intensive Care Medicine at the Washington D.C. Veterans Affairs Medical Center Webinar to be held Wednesday, May 4th at 1 pm EDT HAYWARD, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised s...

April 27, 2022 April 27, 2022 1 EN

TheScreener

An unfavourable environment weighs on ACELRX PHARMACEUTICALS, which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of ACELRX PHARMACEUTICALS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date November 30, 2021, the closing price was USD 0.65 and its target price was estimated at USD 0.46.

Free Trial

December 1, 2021 December 1, 2021 1 EN

Vermilion Research

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EUR 46.83

February 10, 2021 February 10, 2021 1 EN

Vermilion Int'l Compass: Global Equity Strategy

Pullback Underway A pullback in global equities is underway following steep uptrend violations on the MSCI ACWI (ACWI-US) and EURO STOXX 50. These two indexes are already 4-5% off their highs, so further downside may be limited. Several 5%-10% pullbacks are to be expected in any given year -- particularly after the historic 5-month rallies -- so we view this as healthy and normal within the ongoing bull market. ACWI-US is currently testing important support at $105; if this area were to break, next major supports are $102 and $99. A pullback to $102 would be 7-8% off the highs, while a test o...

EUR 46.83

15h / 3m 15h / 3m 1 EN

Dave Nicoski ... (+2)

Dave Nicoski
Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Pullback Finally Begins; Testing 2-Month Supports We have discussed for months that we will need to see the S&P 500 and Nasdaq 100 (QQQ) close below their 20-day MAs/21-day EMAs for more than 2-3 consecutive days in order to get more cautious. While this has not happened yet (only two consecutive days so far, yesterday and Friday), it does appear to be going in that direction as the U.S. dollar (DXY) climbs to test major $106 resistance, and amid 10- and 30-year Treasury yields breaking above long-term resistances. Caution is warranted. Still, in order for there to be a meaningful pullbac...

EUR 46.83

April 16, 2024 April 16, 2024 1 EN

Dave Nicoski ... (+2)

Dave Nicoski
Ross LaDuke

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Market Dynamics Shifting? We have discussed for months that we will need to see the S&P 500 and Nasdaq 100 (QQQ) close below their 20-day MAs/21-day EMAs for more than 2-3 consecutive days in order to get more cautious. While this has not happened yet, it does appear to be going in that direction as the U.S. dollar (DXY) climbs to test major $106 resistance, and amid 10- and 30-year Treasury yields breaking above long-term resistances. Still, in order for there to be a meaningful pullback, important 2-month supports would need to break, including at 4983-5050 on the S&P 500 and $425-$433 on Q...

EUR 46.83

April 15, 2024 April 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Vermilion Booster Shots: Attractive bottom-fishing stocks

AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program

An unfavourable environment weighs on ACELRX PHARMACEUTICALS, which sees a downgrade to Negative

Vermilion Booster Shots: Attractive bottom-fishing stocks

Vermilion Int'l Compass: Global Equity Strategy

Vermilion Compass: Weekly Equity Strategy

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe